AU2003259765B2 - Peptides as solubilizing excipients for transforming growth factor Beta proteins - Google Patents

Peptides as solubilizing excipients for transforming growth factor Beta proteins Download PDF

Info

Publication number
AU2003259765B2
AU2003259765B2 AU2003259765A AU2003259765A AU2003259765B2 AU 2003259765 B2 AU2003259765 B2 AU 2003259765B2 AU 2003259765 A AU2003259765 A AU 2003259765A AU 2003259765 A AU2003259765 A AU 2003259765A AU 2003259765 B2 AU2003259765 B2 AU 2003259765B2
Authority
AU
Australia
Prior art keywords
protein
q283
seq id
peptide
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003259765A
Other versions
AU2003259765A1 (en
Inventor
Pilarin E. L. Nichols
Bernardo Perez-Ramirez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40273302P priority Critical
Priority to US60/402,733 priority
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to PCT/US2003/025177 priority patent/WO2004014940A2/en
Publication of AU2003259765A1 publication Critical patent/AU2003259765A1/en
Application granted granted Critical
Publication of AU2003259765B2 publication Critical patent/AU2003259765B2/en
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/801Collagen, gelatin or derivatives thereof

Description

WO 2004/014940 PCT/US2003/025177 PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR I PROTEINS Field of the Invention [001] The invention relates generally to excipients and agents which solubilize proteins. In particular, the invention relates to compositions for, and methods of, maintaining or increasing the solubility of a protein under various biochemical conditions. The invention also relates to methods of, and compositions for, resolubilizing a protein which has precipitated out of solution. In a particular aspect, the invention relates to compositions for, and methods of, maintaining or increasing the solubility of proteins that belong to the transforming growth factor-R (TGF-1) superfamily.

Background of the Invention [002] The TGF-fI superfamily consists of more than 25 different signaling proteins found in both vertebrates and invertebrates. Protein members of the TGF-f superfamily influence a wide range of biological processes including cell growth, cell growth inhibition, tissue repair, cell differentiation, apoptosis, establishment of the dorso-ventral embryo body axis, and secretion of extracellular matrix components (Ebendal et al. 1998, Journal of Neuroscience 51:139). Thus, members of the TGF- [a superfamily provide attractive targets for the development of pharmaceutical agonists and antagonists that may be used to treat a wide variety of human diseases and conditions which are affected by the activity of one or more of the superfamily members. For example, antagonists and agonists of TGF-1 superfamily members have practical application in the area of tissue repair and regeneration as well as in the area of differentiation of pluripotent stem cells into cells or tissues of a preferred lineage. Additionally, TGF-B superfamily members also provide targets for gene therapy. The cloning and expression of many members of the family has been described. (See e.g. U.S. Patent Nos. 4,877,864; 5,108,922; 5,013,649; 5,116,738; 5,106,748; 5,187,076; WO 2004/014940 PCT/US2003/025177 5,141,905; 5,688,678; 5,661,007; 5,637,480; 5,639,638; 5,658,882; and 5,635,372).

[003] Among the members of the TGF-i superfamily are the bone morphogenetic proteins (BMP). BMPs were initially identified as regulators of cartilage and bone formation. Subsequent work has shown that BMPs, like other TGF-r superfamily members, play a role in many different biological processes including embryogenesis and morphogenesis of a variety of organs and tissues. Additionally, BMPs play a role in the growth, differentiation, and chemotaxis of several different cell types such as hematopoietic cells, epithelial cells, mesenchymal cells, and neuronal cells (Reddi, 1998, Nature Biotechnology 16:247; Ebendal, supra).

[004] BMPs, like other members of the TGF-13 superfamily are highly conserved across different animal species. The mature human BMP-2, for example, is completely homologous with mouse and rat BMP-2. The biologically active form of BMP-2 is a homodimer consisting of a disulfide linked carboxy terminal domain of 114 amino acids. BMP-2 exerts its affect on target cells by binding to a cell surface receptor comprised of a heterooligomer. The receptor is a complex of two serine/threonine kinase receptors (see Ebendal, supra; Reddi supra).

[005] The human homolog of BMP-2 has been cloned, Wozney, 1989, Prog. Growth Factor Res. 1 (4):267. Recombinant human BMP-2 can be expressed as a fragment of the full length BMP-2 consisting of either amino acids 266-396 or 283-396. The fragments form both homodimers and heterodimers resulting in six different isoforms. The six dimeric isoforms are denoted: <Q283/<Q283, <Q283/Q283, Q283/Q283, <Q283/T266, Q283/T266 and T266/T266 and can be separated by cation exchange chromatography (figure The number 283 or 266 refers to the N-terminal amino acid position in the full length rhBMP-2. The letter refers to the amino acid at the N-terminus Q or T) and the refers to the cyclization of the glutamine at position 283 to form pyroglutamic acid. Thus, for example, 00 S<Q283/Q283 refers to a rhBMP-2 disulfide linked dimer wherein one monomer Sof the dimer has the cyclized N-terminal glutamine and the other monomer does Snot.

[006] rhBMP-2 has several clinical applications which require the regeneration of bone. Thus, rhBMP-2 can be used for spinal fusion to treat degenerative disk disease. rhBMP-2 can also be used to treat long bone fractures. It can also be used to treat individuals requiring artificial teeth who lack sufficient bone mass to support the implants.

[007] Maintaining the solubility of a protein is frequently important either for maintaining bio-availability and/or activity of the protein. Protein solubility is dependent upon a variety of factors. These factors include environmental conditions such as pH, salt concentration, temperature and the chemical characteristics of the solvent, as well as innate properties of the protein of interest, such as the primary amino acid sequence and the structural conformation of the protein. Frequently, bio-medical and/or pharmacological applications involving a protein of interest require environmental conditions which do not optimize the solubility of the protein of interest. Precipitation of the protein is the result, thus limiting bio-availability and/or activity of the protein of interest. Accordingly one aspect of the invention is to increase the solubility of a protein of interest, a member of the TGF-3 superfamily, and thereby increase its bio-availability and/or activity either as a pharmaceutical composition or a research reagent.

[008] The instant invention provides increasing the solubility, or inhibiting precipitation, of a protein, by demonstrating that various peptide fragments of rhBMP-2 increase solubility and/or inhibit precipitation of a protein, such as, a member of the TGF-P superfamily.

SUMMARY OF THE INVENTION [009] The invention relates to the discovery that the N-terminus 17 amino acid extension of the T266 isoform of recombinant human BMP-2 (rhBMP-2) and fragments thereof, increase the solubility and/or inhibit precipitation of a protein, such as, rhBMP-2. The invention also relates to the discovery that the W \Mrk Wic khan\70000-799999973873886 7 clan spci 03120S doc -3- 00 O N-terminus 17 amino acid extension of the T266 isoform of rhBMP-2 can 0 resolubilize a protein that has precipitated out of solution. Thus, the invention can be used as an excipient to maintain or increase the solubility of a protein of _interest in a pharmaceutical composition or in a research reagent. The invention can also be used to resolubilize a protein that has precipitated out of solution.

r [010] The invention, therefore, relates to a composition, comprising the N-terminus 17 amino acid extension of the T266 isoform of rhBMP-2, or a fragment thereof, which inhibits the precipitation from a solution, and/or increases the solubility, of a protein of interest. In one embodiment the protein of interest is a member of the TGF-P superfamily, BMP-2, TGF-P, BMP-12, BMP-13, BMP-6. In another embodiment the protein of interest is any one of the rhBMP-2 isoforms, Q283/<Q283, <Q283/Q283 and Q283/Q283.

[01 Oa] The invention further relates to a composition comprising a peptide consisting of SEQ ID NO:1 or a fragment thereof, wherein the fragment comprises amino acids 14-17 of SEQ ID NO:1, is at least 6 amino acids long, and has the ability to increase the solubility of a TGF-p superfamily member protein in solution.

[010b] The invention further relates to a method of inhibiting precipitation of a TGF-P superfamily member protein from solution, comprising contacting the TGF-p superfamily member protein with a peptide comprising amino acids 14-17 of SEQ ID NO:1, wherein the peptide is present in an amount effective to inhibit precipitation of the protein compared to the protein not contacted with the peptide.

[010c] The invention further relates to a method of delivering a pharmaceutical composition to a mammal in need of treatment of a condition or disease comprising administering the pharmaceutical composition to the mammal, wherein the pharmaceutical composition comprises a TGF-p superfamily member protein capable of treating the condition or disease, a peptide comprising amino acids 14-17 of SEQ ID NO:1 and having the ability to increase the solubility of the TGF-P superfamily member protein, and a carrier.

W \Mark Wiclkham\70)X0 -799999\738867\886867 c pci 03120 doc -4- 00 [010d] The invention further relates to a method of resolubilizing a protein Sof interest, the method comprising contacting the protein with a peptide, in an amount effective to resolubilize the protein of interest, wherein the peptide comprises amino acids 14-17 of SEQ ID NO:1.

[011] The invention further relates to a composition comprising a DNA n sequence (SEQ ID NO:2) encoding the N-terminus 17 amino acid extension of the T266 isoform of rhBMP-2, or a fragment thereof, which inhibits the t precipitation from a solution, and/or increases the solubility, of a protein of interest. In one embodiment the protein of interest is a member of the TGF-p c 10 superfamily, BMP-2, TGF-p, BMP-12, BMP-13, BMP-6. In another embodiment the protein of interest is any one of the rhBMP-2 isoforms, e.g., Q283/<Q283, <Q283/Q283 and Q283/Q283.

[012] The invention also relates to a method of inhibiting the precipitation of a protein of interest from solution and/or increasing the solubility of a protein of interest. Said method comprises contacting a protein of interest with a peptide, or a fragment thereof, in an amount sufficient to inhibit precipitation of said protein, wherein said peptide comprises Thr-Phe-Gly-His-Asp-Gly-Lys-Gly- His-Pro-Leu-His-Lys-Arg-Glu-Lys-Arg (SEQ ID W \Mark Wiclham\700000-799999\738867\738867 clc L spci 031208 doc 4a WO 2004/014940 PCT/US2003/025177 NO:1). In one particular embodiment, the peptide is encoded by the DNA sequence comprising ACG TTT GGC CAC GAC GGC AAA GGC CAC CCC CTG CAC AAA AGA GAG AAA AGA (SEQ ID NO:2) in an amount sufficient to inhibit precipitation of said protein. The protein of interest can be any protein. In one embodiment the protein of interest is a member of the TGF-rl superfamily, BMP-2, TGF-11, BMP-12, BMP-13, BMP-6. In another embodiment the protein of interest is at least one of the rhBMP-2 isoform subunits consisting of Q283 or <Q283.

[013] Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or through the practice of the invention. The objects and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.

[014] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

[015] The accompanying figures, which are incorporated in and constitute a part of this specification, and together with the description, serve to explain the principles of the invention.

BRIEF DESCRIPTION OF THE FIGURES [016] Figure 1 is a chromatagram showing the elution profile of the six isoforms of rhBMP-2 eluted off a cation exchange column.

[017] Figure 2 shows rhBMP-2 isoform solubility in 5mM sodium sulfate.

[018] Figure 3 shows the resolubilization of rhBMP-2 isoform Q283/Q283 with rhBMP-2 isoform T266/T266.

[019] Figure 4 shows the resolubilization of rhBMP-2 isoform Q283/Q283 with rhBMP-2 isoform <Q283/T266.

WO 2004/014940 PCT/US2003/025177 [020] Figure 5 shows the solubilization of <Q283/<Q283 with synthetic peptides derived from the N-terminus of the extended form (266- 396) of rhBMP-2.

DESCRIPTION OF THE EMBODIMENTS [021] The invention is based on the surprising discovery that a peptide, derived from rhBMP-2, and fragments thereof, increase the solubility of various isoforms of rhBMP-2. The peptide comprises amino acids 266-282 of rhBMP-2 (SEQ ID NO:1). A fragment is at least 4 amino acids, at least 6 amino acids, at least 8 amino acids, at least 10 amino acids, at least 12 amino acids, at least 14 amino acids, at least 16 amino acids of SEQ ID NO:1. The peptide is also known as the N-terminus 17 amino acid extension of the T266 isoform of rhBMP.

[022] There are six dimeric isoforms of rhBMP-2. The six isoforms include <Q283/<Q283, <Q283/Q283, Q283/Q283, <Q283/T266, Q283/T266 and T266/T266. The T266/T266 dimeric isoform is highly soluble in the presence of sodium sulfate, however its bio-activity is limited compared to the other isoforms. The T266/T266 isoform remains solubilized when dialyzed into salt free or low salt buffer, while the dimers that contain either <Q283 or Q283 isoform subunit precipitate during dialysis to remove salt. The Q283 and <Q283 isoform subunits are truncated at amino acid 283 on the Nterminus. The Q283 isoform subunits thus contain amino acids 283-396 of BMP-2 which is the isoform found in vivo. The 283 isoform subunits do not contain the 17 N-terminus amino acid extension, amino acids 266-282 found on the T266 isoform subunit.

[023] When the 17 amino acid extension is present in the T266 isoform, it confers increased solubility to rhBMP-2. In addition, the 17 amino acid N-terminus of the T266 isoform can resolubilize precipitated isoforms of rhBMP-2. Surprisingly, fragments derived from the 266-282 N-terminus WO 2004/014940 PCTIUS2003/025177 extension of the T266 isoform of rhBMP-2 also confer increased solubility to rhBMP-2 and inhibit precipitation.

[024] Thus, one embodiment of this invention provides methods of increasing the solubility of, inhibiting precipitation of, and resolubilizing the more active forms of rhBMP-2 for use as a pharmaceutical composition or a research reagent. Another embodiment of the invention provides a composition comprising a peptide derived from the T266 isoform of rhBMP, wherein said peptide increases the solubility of a protein of interest, and/or inhibits precipitation of a protein of interest and/or resolubilizies a protein of interest that has precipitated out of solution. In one such embodiment, the composition of the invention comprises the N-terminus 17 amino acid extension of the T266 isoform of rhBMP-2 (SEQ ID NO:1). In another embodiment, the invention comprises a fragment of SEQ ID NO:1, including but not limited to, amino acids 6-17 of SEQ ID NO:1, amino acids 11-17 of SEQ ID NO:1, or amino acids 14-17 of SEQ ID NO:1, that when contacting a protein of interest, increases the solubility of the protein of interest and/or inhibits the precipitation of the protein of interest and/or resolubilzes the protein of interest after it has precipitated from solution. One of skill in the art would understand that to ascertain that a fragment of SEQ ID NO:1 increases solubility of, or inhibits precipitation of a protein of interest, or resolubilizes a protein of interest, the skilled artisan would compare the solubility of, or precipitation of, or resolubilization of the protein of interest, before and after, or with and without, contacting the protein of interest with the fragment of SEQ ID NO:1.

[025] In one embodiment solubility is defined as having an optical density as measured by a spectrophotometer at a wavelength of 340 nanometers of <0.1 when measured in a quartz cuvette with a 1 centimeter pathlength. The spectrophotometer can be for example a Hitachi U-2000.

[026] In one embodiment of the invention, a peptide encoded by SEQ ID NO: or a fragment of a peptide encoded by SEQ ID NO:1, when in WO 2004/014940 PCT/US2003/025177 contact with a protein of interest, results in said protein of interest becoming more soluble and/or less likely to precipitate and/or becoming resolubilized if said protein has already precipitated.

[027] In an alternate embodiment, a peptide encoded by a DNA sequence comprising SEQ ID NO:2 or a fragment of a peptide encoded by a DNA sequence comprising SEQ ID NO:2, when in contact with a protein of interest, results in said protein of interest becoming more soluble and/or less likely to precipitate and/or becoming resolubilized if said protein has already precipitated.

[028] Due to the known degeneracy of the genetic code, wherein more than one codon can encode the same amino acid, a DNA sequence can vary from that shown in SEQ ID NO:2 and, and still encode a polypeptide having the amino acid sequence of SEQ ID NO:1. Such variant DNA sequences can result from silent mutations occurring during PCR amplification), or can be the product of deliberate mutagenesis of a native sequence.

[029] The invention thus provides isolated DNA sequences encoding polypeptides of the invention, selected from: DNA comprising the nucleotide sequence of SEQ ID NO:2; DNA encoding the polypeptides of SEQ ID NO:1; DNA capable of hybridizing to a DNA of or under conditions of moderate stringency and which encodes peptides having the functional properties of the peptides of the invention increases solubility of a protein of interest or resolubilizes a protein of interest); DNA capable of hybridization to a DNA of or under conditions of high stringency and which encodes peptides having the functional properties of the peptides of the invention, and DNA which is degenerate as a result of the genetic code to a DNA defined in or and which encode peptides having the functional properties of the peptides of the invention. Of course, polypeptides encoded by such DNA sequences are encompassed by the invention.

WO 2004/014940 PCT/US2003/025177 [030] As used herein, conditions of moderate stringency can be readily determined by those having ordinary skill in the art based on, for example, the length of the DNA. The basic conditions are set forth by Sambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1, pp.

1.101-104, Cold Spring Harbor Laboratory Press, (1989), and include use of a prewashing solution for the nitrocellulose filters 5X SSC, 0.5% SDS, 1.0 mM EDTA (PH hybridization conditions of about 50% formamide, 6X SSC at about 42 0 C (or other similar hybridization solution, such as Stark's solution, in about 50% formamide at about 42 0 and washing conditions of about 60 0

C,

SSC, 0.1% SDS. Conditions of high stringency can also be readily determined by the skilled artisan based on, for example, the length of the DNA. Generally, such conditions are defined as hybridization conditions as above, and with washing at approximately 68°C, 0.2X SSC, 0.1% SDS. The skilled artisan will recognize that the temperature and wash solution salt concentration can be adjusted as necessary according to factors such as the length of the probe.

[031] In another embodiment, the nucleic acid molecules of the invention also comprise nucleotide sequences that are at least 80% identical to SEQ ID NO:2. Also contemplated are embodiments in which a nucleic acid molecule comprises a sequence that is at least 90% identical, at least identical, at least 98% identical, at least 99% identical, or at least 99.9% identical to SEQ ID NO:2.

[032] The percent identity may be determined by visual inspection and mathematical calculation. Alternatively, the percent identity of two nucleic acid sequences can be determined by comparing sequence information using the GAP computer program, version 6.0 described by Devereux et al. (Nucl.

Acids Res. 12:387,1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The preferred default parameters for the GAP program include: a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted WO 2004/014940 PCT/US2003/025177 comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and no penalty for end gaps. Other programs used by one skilled in the art of sequence comparison may also be used.

[033] The invention also relates to a method of making a protein of interest more soluble or less likely to precipitate from solution, said method comprising genetically engineering said protein by annealing the DNA sequence encoding the N terminus 17 amino acid extension of the T266 isoform of rhBMP (SEQ ID NO:2), or a fragment thereof, to the DNA sequence encoding said protein of interest. The DNA sequence encoding said protein of interest can be any DNA sequence which when translated produces said protein of interest genomic DNA, cDNA). In one embodiment the DNA sequence of the invention (SEQ ID NO:2) or fragment thereof is annealed to the amino terminus of said protein of interest. In another embodiment the DNA sequence of the invention (SEQ ID NO:2) or a fragment thereof is annealed to the carboxy terminus of said protein of interest. The DNA encoding said protein of interest annealed to SEQ ID NO:2 or a fragment thereof can be engineered into any vector or plasmid known in the art. Expression vectors and cloning vectors are described in, for example, Cloning Vectors: A Laboratory Manual (Powells et al. 1985, Supp. 1987) and Molecular Cloning A Laboratory Manual Second Edition (Sambrook et al.

1989, Cold Spring Harbor Laboratory Press) Alternatively, the DNA sequence encoding the protein of interest can be amplified using the polymerase chain reaction (PCR) (Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1989).

[034] The protein of interest annealed to SEQ ID NO:2 may be produced by transformation or transfection of a suitable host cell with all or part of DNA encoding said protein of interest annealed to SEQ ID NO:2 or a WO 2004/014940 PCT/US2003/025177 fragment thereof. Those skilled in the art of molecular biology will understand that any of a wide variety of expression systems may be used to express the DNA encoding the protein of interest annealed to SEQ ID NO:2 or a fragment thereof. The precise host cell used is not critical to the invention. Examples of host cells include, but are not limited to prokaryotic cells such as E. coli or eukaryotic cells such as COS1, CHO, NIH3T3, S. Frugiperda, or S.

cerevisiae. Such cells are readily available from a wide range of sources American Type Culture Collection, Rockland, Md.) The method of transfection and the Choice of expression plasmid or vector will depend on the host system selected. Transformation and transfection methods are described, in Ausubel supra.

[035] The invention also relates to a peptide encoded by SEQ ID NO:1, or a fragment thereof, wherein at least one amino acid within said peptide, or fragment thereof, has been altered by mutation, deletion or substitution with a different amino acid without changing the activity of the peptide, said altered peptide still increases the solubility of, or inhibits precipitation of a protein of interest or alternatively resolubilizes a precipitated protein of interest. In another aspect the invention relates to a peptide encoded by SEQ ID NO:1, or a fragment thereof, wherein at least one amino acid has been added onto the C-terminus. In another aspect the invention relates to a peptide encoded by SEQ ID NO:1, or a fragment thereof, wherein at least one amino acid as been added onto the N-terminus. In yet another embodiment the mutation in the peptide, or fragment thereof, results in an amino acid substitution, wherein said substitution is a conservative substitution. A conservative substitution means substituting one amino acid with another amino acid that has similar chemical properties e.g. polarity, hyrdophobicity, charge. Examples of conservative substitutions include a serine for threonine substitution, or an arginine for lysine substitution, or a valine for alanine substitution. A skilled artisan would understand that many conservative substitutions are possible. In a particular embodiment, the -11- WO 2004/014940 PCT/US2003/025177 altered peptide is at least 70% identical, 80% identical, 90% identical or 99% identical to the peptide encoded by SEQ ID NO:1.

[036] Any technique for mutagenesis known in the art may be used, to generate mutants of the peptide encoded by SEQ ID NO:1, including inter alia, in vitro site-directed mutagenesis (Hutchinson et al., (1978) Biol. Chem.

253:6551; Zoller and Smith, (1984) DNA, 3:479-488; Oliphant et al., (1986) Gene 44:177; Hutchinson et al., (1986) Proc. Natl. Acad. Sci. U.S.A. 83:710; Huygen et al., (1996) Nature Medicine, 2(8):893-898) and use of TAB@ linkers (Pharmacia). PCR techniques may be used for site-directed mutagenesis (Higuchi, 1989, "Using PCR to Engineer DNA", in PCR Technology: Principles and Applications for DNA Amplification, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).

[037] The protein of interest can be any protein. In one aspect of the invention the protein of interest is BMP-2 or rhBMP-2. In another aspect, the protein of interest is at least one of the isoform subunits of rhBMP-2, e.g., <Q283 and Q283. The isoform subunits of rhBMP can exist as monomers or as multimers, e.g. dimers. In yet another aspect, the protein of interest is any member of the TGF-1 superfamily that shares sequence and/or structural homology to BMP-2, TGF-13, BMP-12, BMP-6, BMP-13.

[038] The instant invention also provides for a pharmaceutical composition comprising a peptide encoded by SEQ ID NO:1, or a fragment thereof, amino acids 6-17 of SEQ ID NO:1, amino acids 11-17 of SEQ ID NO:1, or amino acids 14-17 of SEQ ID NO:1, and a biologically active molecule, wherein said peptide encoded by SEQ ID NO:1, or said fragment thereof, increases the solubility of and/or inhibits precipitation of and/or resolubilizes said biologically active molecule and a carrier. In one embodiment the biologically active molecule is a protein or a peptide. Thus, the biologically active molecule can be a member of the TGF-3 superfamily, TGF-2R, BMP-12, BMP-6, BMP-13 or derived from a member of the TGF- B superfamily, a peptide fragment of a TGF-R superfamily member. The -12- WO 2004/014940 PCT/US2003/025177 protein can be, for example, BMP-2 or rhBMP-2. Alternatively, the protein or peptide can be an isoform subunit of rhBMP-2, <Q283 and Q283. Said isoform subunit can be a monomer or a multimer, a dimer. The carrier can be any suitable carrier known in the art. As an example, but not as a limitation, the carrier can be an absorbable collagen sponge (ACS).

[039] The invention relates to a peptide comprising SEQ ID NO:1 or a fragment of SEQ ID NO:1, including, amino acids 6-17 of SEQ ID NO:1, amino acids 11-17 of SEQ ID NO:1, or amino acids 14-17 of SEQ ID NO:1. Said peptide, or fragment thereof, can be made by any method of peptide synthesis known in the art. As an example, but not as a limitation, solid phase peptide synthesis can be employed to make the composition of the invention. Such methods are described, for example, by Steward and Young (Solid Phase Peptide Synthesis (Freeman and Co., San Francisco, 1969).

[040] The peptide encoded by SEQ ID NO:1, or fragment thereof, can be made using recombinant DNA technology. See, the techniques described in Sambrook et al. 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Prokaryotic E. coli) or eukaryotic cells Cos cells, CHO cells) can be used to express the recombinant peptide or fragment thereof, of the invention. Alternatively, an insect system using Autographa californica nuclear polyhedrosis virus (AcNPV) can be used to express the peptide, or fragment thereof, of the invention.

Recombinant insect virus can be grown in Spodoptera frugiperda cells.

[041] The peptide of the invention, or fragment thereof, can be expressed as a fusion protein. Fusion proteins offer the advantages of greater stability and ease of purification of the peptide, or fragment thereof. As an example, but not as limitation, the peptide, or fragment thereof, can be expressed as a GST fusion peptide or a His tagged fusion peptide. Preferably, the fusion tag is cleavable, thus allowing for removal of the tag after the purification step.

WO 2004/014940 PCT/US2003/025177 [042] The invention also relates to a method of delivering a pharmaceutical composition to a mammal in need of treatment of a disease or a condition. The pharmaceutical composition comprises a biologically active molecule and a peptide comprised of SEQ ID NO:1, or fragment thereof. The method comprises administering the pharmaceutical composition to said mammal to treat said condition. The biologically active molecule can be, for example, any member the TGF-R superfamily or other protein that is rendered more soluble, or resolubilizes, when contacted with a peptide comprised of SEQ ID NO:1, or a fragment thereof, compared to the same protein that is not contacted with a peptide comprised of SEQ ID NO: 1, or a fragment thereof.

In one embodiment the biologically active molecule is BMP-2 or rhBMP-2.

[043] The method of the invention can be used to treat any condition requiring the administration of a biologically active molecule wherein said biologically active molecule is more soluble when contacted with a peptide comprised of SEQ ID NO: 1, or a fragment thereof, than without. The method of the invention can be used to treat any condition requiring the administration of a biologically active molecule wherein said biologically active molecule is resolubilized when contacted with a peptide comprised of SEQ ID NO:1, or a fragment thereof. In one embodiment the condition to be treated requires the regeneration of bone, spinal fusion or a long bone fracture and the biologically active molecule BMP-2 or rhBMP-2 or an isoform subunit of rhBMP-2.

[044] The mammal can be any mammal including, but not limited to, a dog, a cat, a rat, a mouse, a primate, a farm animal such as a cow, a goat, a pig, or a sheep. In one embodiment the mammal is a human.

[045] The method of the invention can be practiced under any biochemical and physical conditions that do not interfere with the activity of the SEQ ID NO:I peptide or fragment thereof. As an example, but not as a limitation the method of invention can be practiced at a temperature of 20 0

C

WO 2004/014940 PCT/US2003/025177 and a pH of 4.5 where the peptide is at a concentration of 10-20 fold molar excess of the protein of interest.

[046] Any method known in the art can be used to determine if the method of the invention results in increased solubility of a protein of interest, or results in resolubilization of a protein of interest. As an example, but not as a limitation, measuring the optical density and/or light scattering of the solution containing the protein of interest can be used to determine if the method of the invention increases the solubility of a protein of interest or resolubilizes a protein of interest. Measurements can be taken before and after contacting a protein of interest with a peptide comprised of SEQ ID NO: or a fragment thereof.

[047] The method of the invention can be practiced at a temperature in the range OOC and <65 0 C. In one embodiment the method of the invention is practiced at a temperature of 20 0 C. In another embodiment the method of the invention is practiced at a temperature of 4 0 C. In yet another embodiment, the method of the invention is practiced at a temperature of 370C.

[048] The method of the invention can be practiced at any pH so long as the method results in increased solubility of a protein of interest when contacted with a peptide comprised of SEQ ID NO:1, or a fragment thereof, as compared to the solubility of said protein of interest that is not contacted with a peptide comprised of SEQ ID NO:1, or a fragment thereof. Alternatively, the method of the invention can be practiced at a pH that results in the resolubilization of a protein of interest when contacted with a peptide comprised of SEQ ID NO: 1, or a fragment thereof. Thus, in one embodiment the method of the invention can be practiced at a pH between >1 and In another embodiment the method of the invention is practiced at physiological pH. In yet another embodiment the invention is practiced at a pH of [049] Any concentration of the peptide comprised of SEQ ID NO:1, or a fragment thereof, can be used in the practice of the methods of the WO 2004/014940 PCT/US2003/025177 invention so long as the method results in increased solubility of a protein of interest when contacted with a peptide comprised of SEQ ID NO:1, or a fragment thereof, as compared to the solubility of said protein of interest that is not contacted with a peptide comprised of SEQ ID NO: 1, or a fragment thereof. Alternatively, any concentration of the peptide comprised of SEQ ID NO:1, or a fragment thereof, can be used in the practice of the methods of the invention so long as the method results in the resolubilization of a protein of interest when contacted with a peptide comprised of SEQ ID NO:1, or a fragment thereof. In one embodiment the method of the invention is practiced with a peptide comprised of SEQ ID NO:1, or fragment thereof, at a concentration in the range of 1-1,000 nanomoles. In another embodiment the method of the invention is practiced with a peptide comprised of SEQ ID NO: 1, or fragment thereof, at a concentration in the range of 1-1,000 micromoles. In another embodiment the method of the invention is practiced with a peptide comprised of SEQ ID NO:1, or fragment thereof, at a concentration in the range of 1-1,000 millimoles. In another embodiment the method of the invention is practiced with a peptide comprised of SEQ ID NO: 1, or fragment thereof, at a concentration in the range of 1-1,000 moles.

[050] The method of the invention involves contacting a protein of interest with a peptide comprised of SEQ ID NO:1, or fragment thereof, wherein said peptide or fragment thereof, increases the solubility of the protein of interest or resolubilizes the protein of interest. In one aspect of the invention, the method of the invention is practiced with a peptide comprised of SEQ ID NO:1, or fragment thereof, that is present at a molar excess compared to the protein of interest. The peptide can be present at a molar excess, compared to the protein of interest, in the range of 1-1000-fold molar excess. In another aspect of the invention the method of the invention is practiced with the protein of interest present at a molar excess compared to the peptide comprised of SEQ ID NO:1, or a fragment thereof. The protein of interest can be present at a molar excess, compared to the peptide comprised -16- WO 2004/014940 PCT/US2003/025177 of SEQ ID NO:1, or a fragment thereof, in the range of 1-1000-fold molar excess. In one embodiment the method of the invention is practiced with a peptide comprised of SEQ ID NO:1, or fragment thereof, that is present at a 10-20 fold molar excess compared to the protein of interest.

[051] Other than in the operating example, or where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[052] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. One of skill in the art will appreciate that any numerical value, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[053] The following examples illustrate, but are not intended to limit, the scope of the invention.

Example 1: Solubility of the Six Isoforms of rhBMP-2 [054] rhBMP-2 is produced in CHO cells and contains six dimeric isoforms <Q283/<Q283, Q283/Q283, <Q283/T266, Q283/T266 and T266/T266. The T266 subunit has a 17 amino acid extension on its Nterminus that is lacking in the Q283 and <Q283 subunits. This extension results from the failure of the PACE enzyme to cleave at the C-terminus of Arg 2 82 during cellular processing. This occurs because the recombinant WO 2004/014940 PCT/US2003/025177 protein is overproduced in CHO cells and thus saturates the capacity of the PACE enzyme.

[055] rhBMP-2 has a unique solubility profile. It is most soluble at low salt concentrations and low pH. However, it remains soluble at higher pH values if the salt concentration is increased above an ionic strength of 0.15 M.

To determine if any intrinsic solubility differences existed between the different isoforms of rh-BMP2, the isoforms were purified and treated with 5mM sodium sulfate. The solubility was measured using light scattering at an optical density of 340 nm.

[056] Solubility studies were performed using 5 mM Na 2

SO

4 as a protein precipitating agent. Experiments were performed in 5 mM L-glutamic acid, 5mM NaCI, 2.5% glycine, 0.5% sucrose, 0.01% Polysorbate 80 pH at a protein concentration of 0.5 mg/mL and a volume of 0.5 mL. The incubation period was 10 minutes at room temperature for both precipitation and resolubilization of the molecules. The degree of precipitation was measured by light scattering at 340 nm.

[057] Reverse Phase and Cation Exchange Chromatography were performed on supernatant obtained from rhBMP-2 precipitated with 5mM and 18 mM Na2SO4. The supernatant was separated from the pellet by microcentrifugation at -14,000 RPM for 30 minutes at about 20C to [058] The six dimeric isoforms of rhBMP-2 were separated by cation exchange chromatography (Figure Incubation of a mixture of all six isoforms of rhBMP-2 with low levels of Na 2

SO

4 resulted in an increase in optical density indicative of precipitation of the isoforms. The increase in optical density became apparent at about a range of 3 mM to 4 mM Na 2

SO

4 The amount of precipitated material was determined by reverse phase chromatography by comparing the protein concentration in the starting material with that in the supernatant of the precipitated material. At 5 mM Na 2

SO

4 the protein concentration had decreased by 63% of the original amount. At 18 mM Na 2

SO

4 the protein concentration had decreased by 81% WO 2004/014940 PCT/US2003/025177 of the initial concentration. The supernatants of these precipitates were analyzed by cation exchange chromatography. It was found that the supernatants of the precipitates were enriched for dimers containing the T266 subunit. This initial observation demonstrated a difference in solubility among the six rhBMP-2 isoforms.

[059] To further investigate this phenomena each isoform was purified and incubated with 5 mM Na 2

SO

4 to better assess their relative solubility. Precipitation of the isoforms was measured by light scattering at 340 nM. All isoforms containing the T266 subunit remained clear after addition of 5 mM Na 2

SO

4 All isoforms that contained either the Q283 subunit or the <Q283 subunit but not a T266 subunit became opalescent and resulted in an increase of the optical density at 340 nM. This result indicated that the Q283 and <Q283 isoforms precipitated in the presence of 5mM Na 2

SO

4 while the T266 subunit did not (Figure 2).

[060] The next experiment investigated the ability of the T266/T266 isoform to resolubilize the precipitated Q283/Q283 isoform. Ten nanomoles of Q283/Q283 isoform was precipitated with 5 mM Na 2

SO

4 Varying amounts of the T266/T266 isoform (also in 5 mM Na 2

SO

4 were added to the precipitated Q283/Q283 isoform and the optical density was measured at 340 nM. Addition of the T266/T266 to the precipitated Q283/Q283 isoform resulted in a decrease in the optical density of the solution at 340 nM in a dose dependent manner. Ten nanomoles of Q263/Q263 became clear upon addition of 5 nanomoles of T266/T266. This occurred within ten minutes incubation at room temperature (Figure Addition of the <Q283/T266 isoform to 10 nanomoles of precipitated Q283/Q283 resulted in a similar decrease in optical density at 340 nM, however higher concentrations of the <Q283/T266 isoform were required to achieve the same effect (Figure 4).

[061] The difference between the T266 isoform and the Q283 and <Q283 isoforms is the 17 amino acid extension on the N-terminus of the T266 isoform. The next experiment was performed to determine if the 17 amino WO 2004/014940 PCT/US2003/025177 acid extension, or a fragment thereof, was capable of resolubilizing rhBMP-2.

Peptides corresponding to the 17 amino acid N-terminus of the T266 isoform were synthesized and studies were performed to determine if these peptides could resolubilize the mature rhBMP-2.

[062] The following peptides were synthesized: S17: Thr-Phe-Gly- His-Asp-Gly-Lys-Gly-His-Pro-Leu-His-Lys-Arg-Glu-Lys-Arg (SEQ ID NO:1); S12: Gly-Lys-Gly-His-Pro-Leu-His-Lys-Arg-Glu-Lys-Arg (amino acids 6-17 of SEQ ID NO:1); S7: Leu-His-Lys-Arg-Glu-Lys-Arg (amino acids 11-17 of SEQ ID NO:1); Arg-Glu-Lys-Arg (amino acids 14-17 of SEQ ID NO:1).

[063] All of the synthetic peptides were capable of resolubilizing nanomoles of <Q283/<Q283 that had been precipitated with 5 mM Na 2

SO

4 (Figure The solubilizing capacity decreased with decreasing chain length.

S4, the smallest peptide was still effective at resolubilizing <Q283/<Q283, but required a higher concentration of the peptide.

[064] The ability of the synthetic peptide to resolubilize the <Q283/<Q283 isoform was examined with anions other than sulfate. The peptide was able to resolubilize <Q283/<Q283 precipitated with both sodium chloride and sodium phosphate.

[065] Isoforms of rhBMP-2 that contain the T266 subunit are more soluble than isoforms that contain only the <Q283 or Q283 subunit. The increased solubility, in the presence of various anions is related to the 17 amino acid extension of the T266 subunit.

[066] A peptide comprised of the 17 N-terminus amino acid extension of T266, or a fragment thereof, could be used as an excipient to prevent anion induced precipitation of protein such as rhBMP-2. Because of the high degree of sequence and conformational homology that exists among the members of the TGF-1B superfamily the 17 N-terminus amino acid extension of T266, or a fragment thereof, could be used as an excipient or solubilizing agent for any member of the TGF-B superfamily.

00 O [067] The 17 N-terminus amino acid extension of T266 could be used to Ssolubilize or resolubilize or increase solubility of rhBMP-2. Thus, the peptide or fragments thereof could be used to increase solubility of rhBMP-2 in cases _where production or purification of the protein results in incomplete anion removal from the protein. It could also be used to solubilize rhBMP-2 protein n when it comes in contact with the absorbable collagen sponge (ACS) which is a delivery vehicle for rhBMP-2. The ACS contains uncontrolled levels of multiple anions including sulfate, phosphate and chloride.

EXAMPLE 2: Production of rhBMP-2 With Increased Solubility [068] A DNA fragment encoding the Q283/Q283 isoform of rhBMP with SEQ ID NO: 2 ligated on the N terminus and with flanking BamH1 and Ndel restriction sites is generated by PCR according to methods known in the art.

The PCR product is ligated into the E.coli expression vector pT-16b (Novagen, Madison, WI). This plasmid is then used to transform E. coli JM109. Stimulation of expression of the fusion protein comprising the Q283/Q283 isoform of rhBMP protein with the peptide encoded by SEQ ID NO: 2 is achieved by treating the cells with IPTG. The recombinant protein is isolated by metal chelation chromatography according to methods known in the art Studier et al.

Methods in Enzymology 185:60-89, 1990). The fusion protein exhibits increased solubility compared to the Q283/Q283 isoform of rhBMP and is used for example in a pharmaceutical composition.

[069] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims and the full range of equivalents to which they are entitled.

[069a] The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

W 'Mark Wic hjn\70000-799997388673738867 clen spcci 031208 do -21 00 0 [069b] Throughout the description and claims of the specification, the Sword "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers Sor steps.

W W1ak WLj, \700000-79999973SS67\738S6 ck -,pi03120 d.

-22-

Claims (20)

1. A composition comprising a peptide consisting of SEQ ID NO:1 or a fragment thereof, wherein the fragment comprises amino acids 14-17 of S 5 SEQ ID NO:1, is at least 6 amino acids long, and has the ability to INO increase the solubility of a TGF-P superfamily member protein in N solution. S2. The composition of claim 1, wherein the TGF-P superfamily member protein is BMP-2.
3. The composition of claim 2, wherein the BMP-2 is human BMP-2.
4. The composition of claim 3, wherein the human BMP-2 is rhBMP-2. The composition of claim 4, wherein the rhBMP-2 is chosen from T266, <Q283, or Q283.
6. The composition of claim 5, wherein the rhBMP-2 is a dimer.
7. The composition of claim 6, wherein the dimer is chosen from <Q283/<Q283, <Q283/Q283 and Q283/Q283.
8. The composition of claim 1, wherein the peptide comprises an amino acid sequence chosen from amino acids 6-17 of SEQ ID NO:1 or amino acids 11-17 of SEQ ID NO:1.
9. A method of inhibiting precipitation of a TGF-p superfamily member protein from solution, comprising contacting the TGF-p superfamily member protein with a peptide comprising amino acids 14-17 of SEQ ID NO:1, wherein the peptide is present in an amount effective to inhibit precipitation of the protein compared to the protein not contacted with the peptide. W Mark WicUkhm\700000-799999,738867\738867 clead spcci 031208 do( -23- 00 O The method of claim 9, wherein the peptide is not a bone Smorphogenetic protein or a full-length bone morphogenetic protein c propeptide.
11. The method of claim 9 or claim 10, wherein the peptide consists of SEQ D 5 ID NO:1 or a fragment thereof, wherein the fragment comprises amino Sacids 14-17 of SEQ ID NO:1.
12. The method of any one of claims 9 to 11, wherein the TGF-P c superfamily member protein is BMP-2.
13. The method of claim 12, wherein the BMP-2 is human BMP-2.
14. The method of claim 13, wherein the human BMP-2 is rhBMP-2. The method of claim 14, wherein the rhBMP-2 is chosen from T266, <Q283, or Q283.
16. The method of claim 15, wherein the rhBMP-2 is a dimer.
17. The method of claim 16, wherein the dimer is selected from the group consisting of <Q283/<Q283, <Q283/Q283, or Q283/Q283.
18. The composition of any one of claims 1 to 8, further comprising a pharmaceutically acceptable carrier.
19. The composition of claim 18, wherein the carrier is an absorbable collagen sponge.
20. A method of delivering a pharmaceutical composition to a mammal in need of treatment of a condition or disease comprising administering the pharmaceutical composition to the mammal, wherein the pharmaceutical composition comprises a TGF-p superfamily member protein capable of treating the condition or disease, a peptide comprising amino acids 14-17 of SEQ ID NO:1 and having the ability to W 'Mark WicUikha 700000-799999738867\738867 lcll spci 03120 doc -24- 00 O O increase the solubility of the TGF-p superfamily member protein, and a U carrier. C 21. The method of claim 20, wherein the peptide is not a bone morphogenetic protein or a full-length bone morphogenetic protein In \0 5 propeptide. ir 22. The method of claim 20 or claim 21, wherein the peptide consists of SEQ ID NO:1 or a fragment thereof, wherein the fragment comprises C- amino acids 14-17 of SEQ ID NO:1.
23. A method of resolubilizing a protein of interest, the method comprising contacting the protein with a peptide, in an amount effective to resolubilize the protein of interest, wherein the peptide comprises amino acids 14-17 of SEQ ID NO:1.
24. The method of claim 23 wherein the peptide is not a bone morphogenetic protein or a full-length bone morphogenetic protein propeptide. The method of claim 23 or claim 24 wherein the peptide consists of SEQ ID NO:1 or a fragment thereof, wherein the fragment comprises amino acids 14-17 of SEQ ID NO:1.
26. The composition of claim 1, substantially as hereinbefore described with reference to the Figures and/or Examples.
27. The method of any one of claims 9, 20 and 23, substantially as hereinbefore described with reference to the Figures and/or Examples. W '\Mrk WicUklm\700000.799999\7388t67738867 clkn spcci 031208 doc
AU2003259765A 2002-08-13 2003-08-12 Peptides as solubilizing excipients for transforming growth factor Beta proteins Ceased AU2003259765B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US40273302P true 2002-08-13 2002-08-13
US60/402,733 2002-08-13
PCT/US2003/025177 WO2004014940A2 (en) 2002-08-13 2003-08-12 PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR ß PROTEINS

Publications (2)

Publication Number Publication Date
AU2003259765A1 AU2003259765A1 (en) 2004-02-25
AU2003259765B2 true AU2003259765B2 (en) 2009-01-22

Family

ID=31715891

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259765A Ceased AU2003259765B2 (en) 2002-08-13 2003-08-12 Peptides as solubilizing excipients for transforming growth factor Beta proteins

Country Status (10)

Country Link
US (2) US7241740B2 (en)
EP (1) EP1542711A4 (en)
JP (1) JP2006508049A (en)
CN (1) CN1735426A (en)
AU (1) AU2003259765B2 (en)
BR (1) BR0313429A (en)
CA (1) CA2495222A1 (en)
IL (1) IL166699D0 (en)
MX (1) MXPA05001734A (en)
WO (1) WO2004014940A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259765B2 (en) * 2002-08-13 2009-01-22 Wyeth Peptides as solubilizing excipients for transforming growth factor Beta proteins
US7960935B2 (en) 2003-07-08 2011-06-14 The Board Of Regents Of The University Of Nebraska Robotic devices with agent delivery components and related methods
MX2008015263A (en) * 2006-06-02 2008-12-17 Wyeth Corp Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods.
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
US8679096B2 (en) 2007-06-21 2014-03-25 Board Of Regents Of The University Of Nebraska Multifunctional operational component for robotic devices
EP2397101B1 (en) 2006-06-22 2018-06-13 Board of Regents of the University of Nebraska Magnetically coupleable robotic devices
US9579088B2 (en) 2007-02-20 2017-02-28 Board Of Regents Of The University Of Nebraska Methods, systems, and devices for surgical visualization and device manipulation
EP2170564A4 (en) 2007-07-12 2015-10-07 Univ Nebraska Methods and systems of actuation in robotic devices
JP5475662B2 (en) 2007-08-15 2014-04-16 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ Modular and segmenting the medical device and associated system
CA2695615A1 (en) 2007-08-15 2009-02-19 Board Of Regents Of The University Of Nebraska Medical inflation, attachment, and delivery devices and related methods
JP2014529414A (en) 2010-08-06 2014-11-13 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ Method and system for handling or delivery of natural orifice surgical material
JP6174017B2 (en) 2011-06-10 2017-08-02 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ Vivo vessel sealing end effector and in vivo robotic device
CA2841459A1 (en) 2011-07-11 2013-01-17 Board Of Regents Of The University Of Nebraska Robotic surgical devices, systems and related methods
JP2015531608A (en) 2012-05-01 2015-11-05 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ Tan'anashiki robot equipment and related systems and methods
WO2013191773A1 (en) 2012-06-22 2013-12-27 Board Of Regents Of The University Of Nebraska Local Control Robotic Surgical Devices and Related Methods
US9770305B2 (en) 2012-08-08 2017-09-26 Board Of Regents Of The University Of Nebraska Robotic surgical devices, systems, and related methods
US9888966B2 (en) 2013-03-14 2018-02-13 Board Of Regents Of The University Of Nebraska Methods, systems, and devices relating to force control surgical systems
WO2014160086A2 (en) 2013-03-14 2014-10-02 Board Of Regents Of The University Of Nebraska Methods, systems, and devices relating to robotic surgical devices, end effectors, and controllers
US10342561B2 (en) 2014-09-12 2019-07-09 Board Of Regents Of The University Of Nebraska Quick-release end effectors and related systems and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5108922A (en) 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
ZA8704681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
IT1226552B (en) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Immunostimulatory peptides.
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5688678A (en) 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
DE69228118D1 (en) 1991-06-25 1999-02-18 Genetics Inst BMP 9 compositions
EP2272959A1 (en) 1993-05-12 2011-01-12 Genetics Institute, LLC BMP-11 compositions
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
WO1995005846A1 (en) * 1993-08-26 1995-03-02 Genetics Institute, Inc. Neural regeneration using human bone morphogenetic proteins
DK0733109T3 (en) 1993-12-07 2006-07-03 Genetics Inst Llc BMP-12, BMP-13 and seneinducerende compositions thus
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
US5700774A (en) * 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
ZA9711580B (en) * 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
DE10059336A1 (en) * 2000-11-29 2002-06-13 Scil Proteins Gmbh Preparation of recombinant BMP-2
AU2003259765B2 (en) * 2002-08-13 2009-01-22 Wyeth Peptides as solubilizing excipients for transforming growth factor Beta proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases

Also Published As

Publication number Publication date
US7638495B2 (en) 2009-12-29
US20040102378A1 (en) 2004-05-27
CA2495222A1 (en) 2004-02-19
EP1542711A4 (en) 2009-07-01
CN1735426A (en) 2006-02-15
US7241740B2 (en) 2007-07-10
WO2004014940A3 (en) 2004-12-16
EP1542711A2 (en) 2005-06-22
JP2006508049A (en) 2006-03-09
US20070244050A1 (en) 2007-10-18
BR0313429A (en) 2007-07-31
IL166699D0 (en) 2006-01-15
AU2003259765A1 (en) 2004-02-25
MXPA05001734A (en) 2005-07-22
WO2004014940A2 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
Wozney et al. Novel regulators of bone formation: molecular clones and activities
EP1364655B1 (en) Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
Hiraki et al. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes
US6207813B1 (en) BMP-6 proteins
JP3504263B2 (en) Recombinant bone morphogenic protein heterodimer, compositions and use
KR100205078B1 (en) Basic fibroblast growth factor and the method of preparing the same
EP0394418B1 (en) Osteogenic factors
JP3939729B2 (en) Bmp-12, bmp-13 and their tendons inducing composition
US6310040B1 (en) Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
CA2747490C (en) Insulin analogs
EP1061940B1 (en) Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders
US7425334B2 (en) Methods of making antibodies that bind Nogo
JP3356775B2 (en) Use of a bone morphogenetic protein for bone repair by cooperative combination of the TGF-beta
US6468731B1 (en) Enzyme-mediated modification of fibrin for tissue engineering: incorporation of proteins
JP3045398B2 (en) Protein, dna and its applications
CA2079780C (en) Methods and formulations for stabilizing fibroblast growth factor
JP2656406B2 (en) Vascular endothelial cell growth factor ii
US7459527B2 (en) BMP-7 variants with improved properties
CA2265508C (en) Bone morphogenetic protein-16 (bmp-16) compositions
US7582465B2 (en) Beta secretase genes
WO2006028595A2 (en) Muteins of fibroblast growth factor 21
KR19990014917A (en) Bmp-15 composition
CA2161807A1 (en) Bmp-10 compositions
EP0448704A1 (en) Osteogenic devices
CZ287810B6 (en) DNA sequence, DNA recombinant molecule containing thereof, process for preparing a protein from the TGF-beta substance group, pharmaceutical preparation in which the protein is comprised, antibody or a fragment thereof and use of the antibody

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired